Patients HCP
This site is for US residents only.
Treatment milestones. Al, real SCEMBLIX patient. Al was compensated for his time.

Treatment goals track how well your medication is working

When setting treatment goals, you and your health care team should consider how well the medication is working, and its possible side effects.

Monitor icon
Tracking results
 

Your health care team will monitor your blood regularly to see how your treatment is working. A key measure is the BCR::ABL1 level in your blood: the lower, the better.

Milestone Icon
Measuring response
 

Reaching major molecular response (MMR) is an important treatment milestone. Milestones are measured by the amount of leukemic cells in your blood by checking the abnormal BCR::ABL1 gene levels.

 

MMR is reached when the abnormal gene level in your blood has decreased by at least 1,000 times compared to the level measured at diagnosis.

Information icon

Leukemia experts recognize MMR at Year 1 as an important milestone for patients with CML*  
 

Treatment response milestones 

Based on the body of evidence across TKI therapies in CML, reaching MMR in the first year has been associated with:

  • Very low probability of loss of response to treatment

  • High likelihood of reaching DMR afterward

 

The milestone after MMR is called deep molecular response (DMR)
DMR is the milestone where the response is 10 times larger than MMR. DMR is reached when the abnormal gene level in the blood has decreased by at least 10,000 times (4-log reduction, also called MR4) compared to the level measured at diagnosis.

Hand raise icon
Staying involved
 

Stay actively involved in your treatment and keep your doctor in the loop about all your symptoms and side effects.

Doctor discussion guide icon
Start on a Ph+ CML-CP treatment that may help you achieve your treatment goals
 

Talk to your health care team about your treatment goals and how SCEMBLIX may help.

Download Doctor Discussion Guide

Ph+ CML-CP, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase; TKIs, tyrosine kinase inhibitors.

*Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia V.1.2026. ©National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed July 16, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org ↗. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

†SCEMBLIX was studied vs GLEEVEC® (imatinib), TASIGNA® (nilotinib), Sprycel ® (dasatinib), and Bosulif ® (bosutinib). Sprycel is a registered trademark of Bristol-Myers Squibb Company. Bosulif is a registered trademark of Pfizer Inc.